Guidebook: Achieving consistency in process development of mRNA therapeutics

The importance of raw materials

The SARS-CoV-2 crisis, and the prophylactic mRNA vaccines developed in response to it, brought mRNA to the forefront as an exciting new frontier in medicine. Developers looking to unlock the potential of mRNA therapeutics, however, must overcome a significant challenge—selecting and sourcing raw materials that will allow them to create a consistent therapeutic product at scale.

In this guidebook, developed in collaboration with BioPharma Dive, we share insights into:

  • The role raw materials play in supporting consistency in process development
  • The importance of quality control and the downstream ramifications of choosing suboptimal materials
  • How drug developers can evaluate materials and suppliers to find solutions that meet their needs
  • - Select -
  • Canada
  • United States
What is your current stage of mRNA production?
Would you like to discuss options for mRNA raw materials with our representative?

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.